[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621841":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":29,"collaborators":11,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":11,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":11,"enrollmentInfo":39,"targetDuration":11,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":11},{"fullName":5,"class":6},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Danhong Injection","EXPERIMENTAL",null,[13],"Drug: Danhong injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Control group","PLACEBO_COMPARATOR",[18],"Drug: Saline",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Danhong injection","Danhong Injection for intravenous drip, dosage: 20 ml, diluted in 80 ml of 0.9% saline solution for intravenous drip, twice daily, for a continuous treatment period of 7 days.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Saline","Intravenous drip of 100 ml 0.9% saline solution, twice daily, for 7 consecutive days.",[15],{"type":30,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100621841","phase-2-investigating-the-clinical-benefits-and-underlying-mechanisms-of-danhong-injection-in-modulating-mitochondrial-homeostasis-against-sepsis-associated-myocardial-dysfunction-100621841",false,"NCT07375862","Investigating the Clinical Benefits and Underlying Mechanisms of Danhong Injection in Modulating Mitochondrial Homeostasis Against Sepsis-Associated Myocardial Dysfunction","Inclusion Criteria:\n\n1. Patients who met the Sepsis-3 criteria, defined by a suspected or confirmed infection and an increase in the Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline.\n2. Patients with a diagnosis of sepsis-induced myocardial dysfunction (SIMD).\n\nExclusion Criteria:\n\n1. Patients with significant primary cardiac diseases, including unstable coronary artery disease, severe cardiomyopathy, or severe valvular heart disease.\n2. Exclusion criteria included long-term use of Danhong Injection or recent use of other medication with potential significant impact on cardiac function.\n3. Patients with severe hepatic dysfunction (defined as Child-Pugh class C) or severe renal insufficiency (defined as creatinine clearance \\\u003C30 mL\u002Fmin) were excluded.\n4. Patients with a known allergy to any component of Danhong Injection or a history of severe allergic diathesis were excluded.\n5. Pregnant or lactating women\n6. Patients with severe mental illness or inability to cooperate with the study.\n7. Participation in other drug clinical trials within 3 months prior to enrollment.","ALL","18 Years",{"count":40,"type":41},140,"ESTIMATED","INTERVENTIONAL",[44],"PHASE2","This study aims to evaluate the clinical efficacy of Danhong injection in patients with septic myocardial injury through a prospective randomized controlled trial. The study will enroll 140 patients meeting criteria for septic myocardial injury, divided into a Danhong injection group and a placebo group. Primary endpoints include changes in myocardial injury markers and improvement rates in cardiac function over 7 days, while secondary endpoints include 28-day mortality rates. This will determine whether Danhong injection possesses myocardial protective effects and provide evidence-based support for expanding its clinical indications.",[47],"Sepsis-Induced Myocardial Dysfunction","NOT_YET_RECRUITING","2026-01-22",{"date":51,"type":52},"2026-01-29","ACTUAL",{"date":54,"type":41},"2026-07-01",{"date":56,"type":41},"2028-12-01",{"name":5,"class":6}]